Solriamfetol (Sunosi) for Excessive Daytime Sleepiness

Date: August 26, 2019 Issue #:  1579Summary:  The FDA has approved solriamfetol (Sunosi– Jazz), a dopamine and norepinephrine reuptake inhibitor (DNRI), to improve wakefulness in adults with excessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnea (OSA). Pitolisant(Wakix), an H3-receptor antagonist/inverse agonist recently approved by the FDA for treatment of excessive daytime sleepiness in patients with narcolepsy, will be reviewed in a future issue.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Source Type: research